Jim Cramer Just Discussed These 13 Stocks

8. Bristol-Myers Squibb Company (NYSE:BMY)

Number of Hedge Fund Holders In Q3 2024: 70

Bristol-Myers Squibb Company (NYSE:BMY) is a drug company that sells treatments for liver, nervous system, heart, and other ailments. The firm has performed well on multiple fronts in 2024. Not only has its existing drug pipeline continued to deliver results, but Bristol-Myers Squibb Company (NYSE:BMY)’s hypothesis is also driven by its schizophrenia medicine Cobenfy. Some analysts estimate that the drug can generate more than $10 billion in sales, and Bristol-Myers Squibb Company (NYSE:BMY)’s shares gained 8% over the next couple of days in September after the FDA approved the drug. Cramer is also optimistic about Cobenfy as he shared:

“We pulled the trigger for the charitable trust, can we talk about Thursday meeting, Bristol-Myers. Because this Karuna Therapeutics I think is the single best property out there and they bought it. They didn’t pay much, they’ll be able to make the $14 billion, they’ll be able to make it back. This is the first drug for schizophrenia and bipolar, not, no proof for bipolar but proof for schizophrenia. 30 years and it works. According to everybody.”